Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

Executive Summary

Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data in third-line small cell lung cancer threaten Rova-T's viability for approval.

You may also be interested in...



AbbVie Puts Final Nail In Rova-T's Coffin After Another Trial Failure

AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.

AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments

At J.P. Morgan, AbbVie said the clinical struggles of Rova-T won’t alter its deal-making plans and leave it with plenty of solid tumor possibilities. The pharma took a $4bn write-off of the Stemcentrx deal on Jan. 4.

Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan

All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel